Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Prothena's Revenue for the
three
months ended in Mar. 2026 was €44.19 Mil. Prothena's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Prothena Receivables Turnover Related Terms
Prothena Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Prothena's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0PT vs KYTX, QTTB, RZLT: Receivables Turnover Comparison
For the Biotechnology subindustry, Prothena's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prothena Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prothena's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Prothena's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prothena (FRA:0PT) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Prothena and its competitors. According to the industry distribution chart, Prothena ranks #999999 out of 841 companies in the Biotechnology industry.
Is Prothena's Receivables Turnover too high?
Prothena's current Receivables Turnover is 0.00. Based on the distribution chart, Prothena ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prothena has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Prothena's Receivables Turnover compare to KYTX and QTTB?
According to the Biotechnology industry distribution chart, Prothena ranks #999999 out of 841 companies for Receivables Turnover. This places Prothena in the lower half of its industry. The industry median Receivables Turnover is 5.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Prothena and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prothena's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Prothena (FRA:0PT) has a current Receivables Turnover of 0.00. The stock's GF Value™ is €12.68, compared to a current price of €7.34 — trading 42.1% below its estimated fair value. The current Receivables Turnover is 0.00. Prothena's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Prothena (FRA:0PT), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prothena (FRA:0PT) Overvalued in 2026?
Based on GuruFocus' analysis, Prothena stock appears to be undervalued.
The current stock price of €7.34 is trading 42.1% below its estimated GF Value™ of €12.68.
Key valuation signals for FRA:0PT:
Receivables Turnover: 0.00
GF Value™: €12.68 vs. price of €7.34 (42.1% below fair value)
No single metric tells the full story. See the FRA:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score
Get the complete analysis for FRA:0PT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0PT has been successfully added to your 
